Breaks Categories: News

ThursdayAug 31, 2017 9:20 am

HempNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Announces Clinical Study of High Absorption TurboCBD™ Product

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, this morning announced the world’s first clinical study on human volunteers of cannabidiol (CBD) within Lexaria’s TurboCBD™ product. The study, which aims to evaluate the effects of TurboCBD™ on both cardiovascular health and cognitive function, will have a double-blind and placebo controlled cross-over design measuring effects after a single dose, as well as seven days of daily dosing, in 24 volunteers. “Lexaria is proud to be advancing our collective knowledge of the benefits of CBD specifically showcasing the benefits of…

Continue Reading

WednesdayAug 30, 2017 10:57 am

HempNewsBreaks – PotNetwork Holding, Inc. (POTN) Retains PCAOB-Registered East West Accounting Services, LLC to Initiate Audit

PotNetwork Holding, Inc. (OTC: POTN) this morning announced that it has officially retained the auditing services of East West Accounting Services, LLC, a Public Company Accounting Oversight Board (PCAOB) registered CPA firm based in South Florida. Moving forward, East West will review and analyze PotNetwork’s recently announced financial results, providing credible verification of the company’s second quarter and year-to-date operating performance. “We believe that the timing for this action is now,” Gary Blum, chief executive officer of PotNetwork Holding, stated in the news release. “In consideration of the amount of momentum built up over the past 6 months, coupled with…

Continue Reading

TuesdayAug 29, 2017 9:31 am

HempNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Scheduled to Attend Two Cannabis Conferences in September

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, this morning announced its plans to attend two cannabis investment conferences in September. The first, the Investorshub International Cannabis Conference, will be held at the JW Marriott in downtown Los Angeles on September 1-2. The second, the Institutional Capital & Cannabis Conference (East), is scheduled to take place on September 7-8 in Miami Beach. This morning’s news release also included an update on the company’s financing activities. Notably, Lexaria has received and executed a notice of conversion related to certain…

Continue Reading

MondayAug 28, 2017 11:02 am

HempNewsBreaks – Global Payout, Inc. (GOHE) Targeting Cannabis Industry through Launch of Bitcoin Payment Solution

Payment solutions company Global Payout, Inc. (OTC: GOHE) this morning announced that it will incorporate bitcoin as a payment method for retail and wholesale customers in the cannabis industry, providing a solution for the banking issues that currently face legal cannabis businesses. In support of this initiative, the company’s majority-owned subsidiary, MoneyTrac Technology, Inc., will leverage its virtual financial wallet technology to eliminate cash payments for cannabis at retail stores. “Since there is an inability to access commercial banks for merchant bank accounts, we feel it is imperative to focus on currency alternatives such as bitcoin to service cannabis industry…

Continue Reading

MondayAug 28, 2017 9:55 am

HempNewsBreaks – PotNetwork Holding, Inc. (POTN) Takes Center Stage at Mayweather-McGregor with Sponsorship Deal

PotNetwork Holding, Inc. (OTC: POTN) this morning announced that its wholly-owned subsidiary, Diamond CBD, Inc., was an official sponsor of two contenders at the Mayweather-McGregor Event that took place on August 26. “We want to thank Francisco Fonseca and Steve Cunningham for the opportunity to gain this monumental level of brand exposure,” Gary Blum, chief executive officer of PotNetwork Holding, stated in the news release. “In consideration of what is paid for a 30 second commercial spot, during a comparable sporting event, we believe that this is one of the most exciting opportunities for public exposure that Diamond CBD and…

Continue Reading

MondayAug 28, 2017 9:15 am

HempNewsBreaks – ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) Announces Release of High Level CBD Product

ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced the release of one of Canada’s highest legal CBD:THC ratio products by wholly-owned subsidiary ABcann Medicinals Inc. CBD-Med has a ratio of 27.6:1 (18.5% CBD to 0.67% THC), making it one of Canada’s highest CBD products under Health Canada regulations. “The development of these products is in line with ABcann's corporate strategy as a premium product provider of organic, pesticide free cannabis,” Ken Clement, executive chairman of ABcann, stated in the news release. “As the Company continues to scale production capacity, our product line will expand as we strive to…

Continue Reading

ThursdayAug 24, 2017 9:18 am

HempNewsBreaks – PotNetwork Holdings, Inc. (POTN) Subsidiary Achieves 30% Month-Over-Month Revenue Growth in July

PotNetwork Holdings, Inc. (OTC: POTN) this morning announced that its wholly owned subsidiary, Diamond CBD, Inc., has delivered a considerable month-over-month increase in revenues, recording $1,459,137 for the month of July. This total exceeded the company’s June revenues by more than 30 percent. “We are very pleased with how the numbers have continued to gain over the summer,” Maria Gomez, regional vice president of sales for Diamond CBD, Inc., stated in the news release. “We are consistently setting new sales records month after month and are excited to be able to report this type of continuing growth. We have taken…

Continue Reading

ThursdayAug 10, 2017 9:53 am

HempNewsBreaks – Arcadia Biosciences, Inc. (NASDAQ: RKDA) and Bioceres’ Joint Venture Receives Completed Safety Review by FDA

Arcadia Biosciences (NASDAQ: RKDA) before the bell said its joint venture with Bioceres S.A., Verdeca, has received notification that the FDA has completed its full review of the company’s safety evaluation for HB4 soybeans. This permits Verdeca products derived from HB4 soybeans to be used commercially in human food and animal feed. Additionally, completion of the FDA’s review marks a key regulatory achievement in the approval process for Verdeca’s HB4 drought stress tolerance trait. The company has submitted an environmental safety data petition to the U.S. Department of Agriculture (USDA) which is currently under review. The USDA is expected to…

Continue Reading

ThursdayAug 10, 2017 9:49 am

HempNewsBreaks – Data and Safety Monitoring Board Recommends Completion of ARCA biopharma, Inc.’s (NASDAQ: ABIO) GENETIC-AF Trial

ARCA biopharma (NASDAQ: ABIO) this morning said the GENETIC-AF trial Data and Safety Monitoring Board (DSMB) has completed its pre-specified phase 2B interim analysis and has recommended completion of the study with no changes to the trial design. GENETIC-AF is a clinical trial evaluating Gencaro™ as a candidate for the treatment of atrial fibrillation (AF). The Gencaro development program has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). “The DSMB stated that there were no safety concerns and that the efficacy results met the prespecified criteria for continuing the Phase 2B trial to completion. We…

Continue Reading

ThursdayAug 10, 2017 9:32 am

HempNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) CEO Discusses Company’s Progress in Interview

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, this morning announced that its chief executive officer, Chris Bunka, was featured in a recent interview on the Uptick Network Stock Day Radio Show. Bunka leveraged the platform to discuss Lexaria’s overall accomplishments in the past three months, as well as the company’s expectations for profitability moving forward. He notes that ongoing research and development programs could open both the NSAID and Nicotine markets to Lexaria, providing an opportunity to significantly increase corporate revenues and facilitate further expansion. “In the…

Continue Reading